Piper Sandler analyst David Amsellem reiterated an Overweight rating and $45.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN) after a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE